(SPPL3) in the Shedding Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1. -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
Dysfunctional Γ-Secretase in Familial Alzheimer's Disease
HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neurochem Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2019 July 01. Published in final edited form as: Neurochem Res. 2019 January ; 44(1): 5–11. doi:10.1007/s11064-018-2511-1. Dysfunctional γ-secretase in familial Alzheimer’s disease Michael S. Wolfe Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 USA. Abstract Genetics strongly implicate the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer’s disease. Dominant missense mutation in the presenilins and the amyloid precursor protein (APP) cause early-onset familial Alzheimer’s disease (FAD). As presenilin is the catalytic component of the γ-secretase protease complex that produces Aβ from APP, mutation of the enzyme or substrate that produce Aβ leads to FAD. However, the mechanism by which presenilin mutations cause FAD has been controversial, with gain of function and loss of function offered as binary choices. This overview will instead present the case that presenilins are dysfunctional in FAD. γ-Secretase is a multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and processive manner. Reduction in a specific function—the carboxypeptidase trimming of initially formed long Aβ peptides containing most of the transmembrane domain to shorter secreted forms —is an emerging common feature of FAD-mutant γ-secretase complexes. Keywords amyloid; protease; genetics; biochemistry Introduction The deposition of extracellular amyloid plaques and neurofibrillary tangles in the brain are cardinal pathological features of Alzheimer’s disease (AD) (Goedert and Spillantini, 2006). The former are composed primarily of the amyloid β-peptide (Aβ), while the latter are comprised of filaments of the otherwise microtubule-associated protein tau. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Reduced Reelin Expression Accelerates Amyloid-ßplaque
9228 • The Journal of Neuroscience, July 7, 2010 • 30(27):9228–9240 Neurobiology of Disease Reduced Reelin Expression Accelerates Amyloid- Plaque Formation and Tau Pathology in Transgenic Alzheimer’s Disease Mice Samira Kocherhans,1* Amrita Madhusudan,1* Jana Doehner,1* Karin S. Breu,1 Roger M. Nitsch,2 Jean-Marc Fritschy,1 and Irene Knuesel1 1Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland, and 2Division of Psychiatry Research, University of Zurich, CH-8008 Zurich, Switzerland In addition to the fundamental role of the extracellular glycoprotein Reelin in neuronal development and adult synaptic plasticity, alterations in Reelin-mediated signaling have been suggested to contribute to neuronal dysfunction associated with Alzheimer’s disease (AD). In vitro data revealed a biochemical link between Reelin-mediated signaling, Tau phosphorylation, and amyloid precursor protein (APP) processing. To directly address the role of Reelin in amyloid- plaque and Tau pathology in vivo, we crossed heterozygous Reelin knock-out mice (reeler) with transgenic AD mice to investigate the temporal and spatial AD-like neuropathology. We demonstrate that a reduction in Reelin expression results in enhanced amyloidogenic APP processing, as indicated by the precocious production of amyloid- peptides, the significant increase in number and size of amyloid- plaques, as well as age-related aggravation of plaque pathology in double mutant compared with single AD mutant mice of both sexes. Numerous amyloid- plaques accumulate in the hippocampal formation and neocortex of double mutants, precisely in layers with strongest Reelin expression and highest accumulation of Reelin plaques in aged wild-type mice. Moreover, concentric accumulations of phosphorylated Tau-positive neurons around amyloid- plaques were evident in 15-month-old double versus single mutant mice. -
And SPP-Like Proteases☆
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1828 (2013) 2828–2839 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamem Review Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases☆ Matthias Voss a, Bernd Schröder c, Regina Fluhrer a,b,⁎ a Adolf Butenandt Institute for Biochemistry, Ludwig-Maximilians University Munich, Schillerstr. 44, 80336 Munich, Germany b DZNE — German Center for Neurodegenerative Diseases, Munich, Schillerstr. 44, 80336 Munich, Germany c Biochemical Institute, Christian-Albrechts-University Kiel, Olshausenstrasse 40, 24118 Kiel, Germany article info abstract Article history: Signal peptide peptidase (SPP) and the homologous SPP-like (SPPL) proteases SPPL2a, SPPL2b, SPPL2c and Received 27 December 2012 SPPL3 belong to the family of GxGD intramembrane proteases. SPP/SPPLs selectively cleave transmembrane Received in revised form 25 March 2013 domains in type II orientation and do not require additional co-factors for proteolytic activity. Orthologues of Accepted 29 March 2013 SPP and SPPLs have been identified in other vertebrates, plants, and eukaryotes. In line with their diverse subcellular localisations ranging from the ER (SPP, SPPL2c), the Golgi (SPPL3), the plasma membrane Keywords: (SPPL2b) to lysosomes/late endosomes (SPPL2a), the different members of the SPP/SPPL family seem to Regulated intramembrane proteolysis fi Intramembrane-cleaving proteases exhibit distinct functions. Here, we review the substrates of these proteases identi ed to date as well as GxGD proteases the current state of knowledge about the physiological implications of these proteolytic events as deduced Signal peptide peptidase from in vivo studies. -
Supplementary Data
Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type -
Evaluating the Potential Therapeutic Role of Angiotensin Converting
Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model by Sarah Gomes A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Sarah Gomes 2017 Evaluating the Potential Therapeutic Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Alzheimer’s Disease using a Drosophila Model Sarah Gomes Master of Science Institute of Medical Science University of Toronto 2017 Abstract Presenilins (PS) play a role in familial Alzheimer’s disease (AD) and Notch signalling. In a genetic screen looking for modifiers of APP but not Notch, we identified Drosophila orthologs of Angiotensin Converting Enzyme (ACE). Interestingly, ACE polymorphisms are associated with AD and Apo-E, the best characterized risk factor for late-onset AD. Moreover, ACE inhibitors (ACE-I) delayed the onset of cognitive impairment and neurodegeneration in mice and humans. However, it remains unclear why ACE-I are beneficial in AD. Here, we explore the link between PS and ACE in a Drosophila model using genetics and pharmacology. We found that ACE disruption does not affect Notch related phenotypes. Moreover, we found that ACE-I and Angiotensin Receptor Blockers are beneficial in an AD Drosophila model. Since inhibition of ACE has no detrimental effects on Notch and modulates AD related phenotypes, it could provide an important therapeutic target for AD. ii Acknowledgments I would like to begin by thanking my supervisor, Gabrielle Boulianne, for her support and guidance. She has not only taught me how to think like a scientist, but also how to create a work- life balance. -
Plant Signaling Peptides, Novel Insights Into Their Processing and Role in Root Development
Plant signaling peptides, novel insights into their processing and role in root development Sarieh Ghorbani 2014 Cover: GLV10 expression pattern during lateral root primordia development To my wonderful parents, Samarrokh and Bohloul ی ن هم ه ثم بهل تقد م هب مهربای اه و را ی اهی پدر و مارد زعزیم، ررخ و ول يک چند هب کودکی هب استاد شدیم يک چند هب استادی خود شاد شدیم سخ اپيان ن شنو هک ما را هچ رسيد از خاک رب آدمیم و رب باد شدیم حکیم عمر خیام Myself, when young did eagerly frequent Doctor and Saint, and heard great Argument About it and about: but evermore Came out by the same Door where in I went. Omar Khayyam (Persian poet, mathematician, astronomer, 1048 –1131) (translated by Edward FitzGerald) Ghent University Faculty of Sciences Department of Plant Biotechnology and Bioinformatics Plant signaling peptides, novel insights into their processing and role in root development Sarieh Ghorbani Promoters: Prof. Dr. Tom Beeckman and Dr. Pierre Hilson April 2014 VIB – Plant Systems Biology Thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Science: Biochemistry and Biotechnology Promoters: Prof. Dr. Tom Beeckman Department of Plant Systems Biology, VIB and Department of Plant Biotechnology and Bioinformatics, Ghent University [email protected] Dr. Pierre Hilson Institut Jean-Pierre Bourgin, UMR1318 INRA-AgroParisTech, Versailles Cedex, France [email protected] Examination commission: Prof. Dr. Ann Depicker (Chair) Department of Plant Systems Biology, VIB and Department of Plant Biotechnology and Bioinformatics, Ghent University [email protected] Prof. Dr. -
Ubiquitinations in the Notch Signaling Pathway
Int. J. Mol. Sci. 2013, 14, 6359-6381; doi:10.3390/ijms14036359 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Ubiquitinations in the Notch Signaling Pathway Julien Moretti 1 and Christel Brou 2,* 1 Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA; E-Mail: [email protected] 2 Institut Pasteur and CNRS URA 2582, Signalisation Moléculaire et Activation Cellulaire, 25 rue du Docteur Roux, 75724 Paris cedex 15, France * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +33-1-40-61-30-41 Fax: +33-1-40-61-30-40. Received: 1 February 2013; in revised form: 11 March 2013 / Accepted: 14 March 2013 / Published: 19 March 2013 Abstract: The very conserved Notch pathway is used iteratively during development and adulthood to regulate cell fates. Notch activation relies on interactions between neighboring cells, through the binding of Notch receptors to their ligands, both transmembrane molecules. This inter-cellular contact initiates a cascade of events eventually transforming the cell surface receptor into a nuclear factor acting on the transcription of specific target genes. This review highlights how the various processes undergone by Notch receptors and ligands that regulate the pathway are linked to ubiquitination events. Keywords: Notch; ubiquitination; deubiquitinating enzyme; signal transduction; trafficking 1. Introduction Development and maintenance of organs and tissues requires constant interaction and communication between cells. One of the major signaling pathways involved in cell-cell communication is the Notch pathway. This pathway is highly conserved in animals as distantly related as C. -
Regulated Signaling and Alzheimer's Disease
Chapter 4 γ-Secretase — Regulated Signaling and Alzheimer's Disease Kohzo Nakayama, Hisashi Nagase, Chang-Sung Koh and Takeshi Ohkawara Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54230 1. Introduction Alzheimer’s disease (AD) is an incurable and progressive neurodegenerative disorder and the most common form of dementia that occurs with aging. The main hallmarks of this disease are the extracellular deposition of amyloid plaques and the intracellular aggregation of tangles in the brain [1, 2]. Although the causes of both the onset and progression of AD are still uncertain, much evidence, including results of genetic analysis, indicates that amyloid precursor protein (APP) itself and its proteolytic processing are responsible for AD. Indeed, familial forms of AD (FAD) have mutations [3] or a duplication of the APP gene [4] or mutations in the presenilin1 or 2 (PS1 or PS2) genes [5-7] that code for a catalytic component of the γ-secretase complex [8]. Although APP plays a central role in AD [1, 2], the physiological function of this membrane protein is not clear [9]. On the other hand, γ-secretase was first identified as a protease that cleaves APP within the transmembrane domain and produces amyloid-β (Aβ) peptides [10], which are the main constituent of amyloid plaques and are thought to be involved in AD pathogenesis. However, similar to the physiological functions of APP, those of γ-secretase are also still unclear [11, 12]. The signaling hypothesis suggests that the primary function of γ-secretase is to regulate signal‐ ing of type 1 membrane proteins (the amino terminus is extracellular, and the carboxy terminus is cytoplasmic); this was proposed by analogy of Notch signaling [13-15]. -
CSF-Apoer2 Fragments As a Read-Out of Reelin Signaling Distinct Patterns
Clinica Chimica Acta 490 (2019) 6–11 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/cca CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in T sporadic and autosomal-dominant Alzheimer disease Inmaculada Lopez-Fonta,b,1, Guillermo Iborra-Lazaroa,b,1, Raquel Sánchez-Vallec, ⁎ ⁎ José-Luis Molinuevoc, Inmaculada Cuchillo-Ibañeza,b, , Javier Sáez-Valeroa,b, a Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 Sant Joan d'Alacant, Spain b Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain c Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, 08036 Barcelona, Spain ARTICLE INFO ABSTRACT Keywords: Reelin is a glycoprotein associated with synaptic plasticity and neurotransmission. The malfunctioning of reelin Reelin signaling in the brain is likely to contribute to the pathogenesis of Alzheimer's disease (AD). Reelin binding to ApoER2 Apolipoprotein E receptor 2 (ApoER2) activates downstream signaling and induces the proteolytic cleavage of Proteolytic fragment ApoER2, resulting in the generation of soluble fragments. To evaluate the efficiency of reelin signaling in AD,we CSF have quantified the levels of reelin and soluble ectodomain fragments of ApoER2 (ectoApoER2) inthecere- Autosomal-dominant AD brospinal fluid (CSF). CSF from sporadic AD patients (sAD; n = 14, age 54–83 years) had lower levels of ecto- Sporadic AD ApoER2 (~31% reduction; p = .005) compared to those in the age-matched controls (n = 10, age 61–80), and a higher reelin/ecto-ApoER2 ratio. In contrast, autosomal dominant AD patients, carriers of PSEN1 mutations (ADAD; n = 7, age 31–49 years) had higher ecto-ApoER2 levels (~109% increment; p = .001) and a lower reelin/ecto-ApoER2 ratio than the non-mutation carriers from the same families (n = 7, age 25–47 years).